Chimeric antigen receptor (CAR) T cells are an exciting advancement in cancer
immunotherapy, with striking success in hematological cancers. However, in solid tumors …

From the 1960s to the early 2000s, alkylating agents (eg, melphalan, cyclophosphamide,
and bendamustine) remained a key component of standard therapy for newly-diagnosed or …

Competent T-cells with sufficient levels of fitness combat cancer formation and progression.
In multiple myeloma (MM), T-cell exhaustion is caused by several factors including tumor …

Chimeric Antigen Receptor (CAR) T-cell therapy is a promising treatment option for patients
suffering from B-cell-and plasma cell-derived hematologic malignancies and is being …

Abstract While CAR-T and tgTCR-T therapies have exhibited noteworthy and promising
outcomes in hematologic and solid tumors respectively, a set of distinct challenges remains …

Simple Summary Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the
treatment of specific hematological diseases, but is unsuccessful in around 60% of patients …

Background: Gene therapy involves delivering therapeutic genomic material to a target
tissue to modify expression of a protein or induce other characteristic changes. Recent …

La terapia con células T portadoras de antígeno quimérico (CAR), es una forma de
inmunoterapia adoptiva para neoplasias. Los resultados obtenidos con formas refractarias …

Chimeric antigen receptor T cells (CAR-T) are T cells that have been genetically modified to
express a receptor that recognizes a specific target molecule. When T cells bind to their …